Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Woody Massey"'
Autor:
Margaret Johnson, David Casarett, Katherine B. Peters, Eric S. Lipp, James E. Herndon, Henry S. Friedman, Dina Randazzo, Luis Ramirez, Mary Lou Affronti, Annick Desjardins, Woody Massey, Jung-Young Kim, David M. Ashley
Publikováno v:
Neuro Oncol
OBJECTIVE There is no validated model for delivering palliative care (PC) in the glioblastoma (GBM) population. The primary objectives were to assess the feasibility and determine the acceptability of a time-based model of integrated specialty PC to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e17d67916c6d21f083f6267e9b52cb7
https://europepmc.org/articles/PMC6846910/
https://europepmc.org/articles/PMC6846910/
Autor:
Gordana Vlahovic, Elizabeth Miller, Henry S. Friedman, Dina Randazzo, Woody Massey, James E. Herndon, Alex Mannerico, Mary Lou Affronti, Deborah Iden, Frances McSherry, Eric S. Lipp, Katherine B. Peters, Annick Desjardins
BACKGROUND: Prognosis of recurrent MG remains poor with a median survival of 3-11 months for patients on BEV-containing regimens. Few active evidence-based treatments are available & response rates have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a7c9faabd555ed5e696e296ae235d0f
https://europepmc.org/articles/PMC4638552/
https://europepmc.org/articles/PMC4638552/
Autor:
Eric S. Lipp, Dina Randazzo, David A. Reardon, James E. Herndon, Katherine B. Peters, Ashley Ghiaseddin, Annick Desjardins, Henry S. Friedman, Woody Massey, Frances McSherry, Alex Mannerino
Publikováno v:
The Oncologist
Lessons Learned Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma. Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression-free
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c8af81b956cb47050d2ec789140150
https://doi.org/10.1634/theoncologist.2017-0501
https://doi.org/10.1634/theoncologist.2017-0501
Autor:
Margaret Johnson, Ivan D. Horak, James E. Herndon, Frances McSherry, Annick Desjardins, Paul Nadler, Dina Randazzo, Henry S. Friedman, Katherine B. Peters, Eric S. Lipp, Woody Massey
Publikováno v:
Neuro-Oncology. 19:vi14-vi14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1ffa5a4d98cbe7375b6a7e3d07fd81
https://doi.org/10.1093/neuonc/nox168.052
https://doi.org/10.1093/neuonc/nox168.052
Autor:
Gordana Vlahovic, Henry S. Friedman, Ashley Ghiaseddin, David A. Reardon, Alexandra Mannerino, Annick Desjardins, James E. Herndon, Woody Massey, Katherine B. Peters, Dina Randazzo, Frances McSherry, Eric S. Lipp
Publikováno v:
Journal of Clinical Oncology. 33:2034-2034
2034 Background: Prognosis for recurrent glioblastoma (GBM) remains dismal with a 9-15% 6-month progression-free survival (PFS). However, the addition of bevacizumab (BEV), a humanized monoclonal I...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dafcbe6112476d4e1c10e4ea8b7f1f54
https://doi.org/10.1200/jco.2015.33.15_suppl.2034
https://doi.org/10.1200/jco.2015.33.15_suppl.2034
Autor:
Woody Massey, James E. Herndon, Patrick Healy, Gordana Vlahovic, Rashida A. Karmali, Elizabeth Miller, Susan Boulton, Dina Randazzo, Annick Desjardins, Eric S. Lipp, Katherine B. Peters, Henry S. Friedman
Publikováno v:
Journal of Clinical Oncology. 33:2067-2067
2067 Background: BEV is approved for the treatment of recurrent glioblastoma pts, but there is a lack of effective therapies once a tumor recurs on BEV. CTO, an oral inhibitor of non-voltage-depend...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b4f49717983b89b7808e18a85e5a810
https://doi.org/10.1200/jco.2015.33.15_suppl.2067
https://doi.org/10.1200/jco.2015.33.15_suppl.2067
Autor:
Eric S. Lipp, Jill Tetterton, Sprague Cheshire, Katherine H Kalinowski, Harry H Lay, Annick Desjardins, James J. Vredenburgh, Alise Brickhouse, Frances McSherry, James E. Herndon, Mary Lou Affronti, Woody Massey, Katherine B. Peters, Victoria Poillucci, Henry S. Friedman, Cindy Southerland, Christina Cone, Elizabeth Miller, Jung-Young Kim
Publikováno v:
Journal of Clinical Oncology. 30:2074-2074
2074^ Background: Prognosis of recurrent MG remains poor with a median survival of 3-9 months. Few evidence based treatments are available and response rates have been < 20% with 6 month progression–free survival (PFS) of < 9-16%. Poor prognosis is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b4ef66e43b74d8976f44103655d314d
https://doi.org/10.1200/jco.2012.30.15_suppl.2074
https://doi.org/10.1200/jco.2012.30.15_suppl.2074
Autor:
Alise Brickhouse, Frances McSherry, April Coan, Woody Massey, Annick Desjardins, James E. Herndon, Eric S. Lipp, Henry S. Friedman, Katherine B. Peters, David A. Reardon, James J. Vredenburgh
Publikováno v:
Journal of Clinical Oncology. 30:2027-2027
2027 Background: Prognosis for recurrent glioblastoma (GBM) remains poor with median survival between 3 to 6 months. Use of anti-vascular endothelial growth factor inhibitor, bevacizumab (BEV), has advanced this area of research, but continued studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe2c068a4df2cbf60e4472ce1e6b4233
https://doi.org/10.1200/jco.2012.30.15_suppl.2027
https://doi.org/10.1200/jco.2012.30.15_suppl.2027